Drug interactions between Ethyol and Inderide
| Results for the following 2 drugs: |
|---|
| Ethyol (amifostine) |
| Inderide (hydrochlorothiazide/propranolol) |
Interactions between your selected drugs
propranolol ↔ amifostine
Applies to:Inderide (hydrochlorothiazide/propranolol) and Ethyol (amifostine)
MONITOR: Concomitant use with hypotensive agents may increase the risk and severity of hypotension associated with amifostine. Hypotension has been reported frequently in patients treated with amifostine. It is usually transient (lasting from 5 to 15 minutes) and closely associated with amifostine administration, but may persist or become evident hours after administration. Moreover, hypotension can occur despite adequate hydration and positioning of the patient. Significant drops in systolic blood pressure have been reported, in some cases resulting in premature termination of amifostine infusion. In rare cases, sometimes during or after hypotension, patients have experienced tachycardia, bradycardia, dyspnea, apnea, hypoxia, chest pain, myocardial ischemia, renal failure, myocardial infarction, convulsions, unconsciousness, respiratory arrest, and cardiac arrest.
MANAGEMENT: If medically feasible, antihypertensive medications should be interrupted 24 hours prior to amifostine administration. Blood pressure should be closely monitored during and after treatment. In addition to hypotension, transient hypertension or exacerbation of preexisting hypertension may occur from intravenous hydration, discontinuation of antihypertensive medications, or other causes. Patients who continue their hypotensive medication(s) during amifostine therapy should be carefully monitored for the development of hypotension. Clinical symptoms of hypotension are usually quickly reversed by fluid infusion and postural management.
hydrochlorothiazide ↔ amifostine
Applies to:Inderide (hydrochlorothiazide/propranolol) and Ethyol (amifostine)
MONITOR: Concomitant use with hypotensive agents may increase the risk and severity of hypotension associated with amifostine. Hypotension has been reported frequently in patients treated with amifostine. It is usually transient (lasting from 5 to 15 minutes) and closely associated with amifostine administration, but may persist or become evident hours after administration. Moreover, hypotension can occur despite adequate hydration and positioning of the patient. Significant drops in systolic blood pressure have been reported, in some cases resulting in premature termination of amifostine infusion. In rare cases, sometimes during or after hypotension, patients have experienced tachycardia, bradycardia, dyspnea, apnea, hypoxia, chest pain, myocardial ischemia, renal failure, myocardial infarction, convulsions, unconsciousness, respiratory arrest, and cardiac arrest.
MANAGEMENT: If medically feasible, antihypertensive medications should be interrupted 24 hours prior to amifostine administration. Blood pressure should be closely monitored during and after treatment. In addition to hypotension, transient hypertension or exacerbation of preexisting hypertension may occur from intravenous hydration, discontinuation of antihypertensive medications, or other causes. Patients who continue their hypotensive medication(s) during amifostine therapy should be carefully monitored for the development of hypotension. Clinical symptoms of hypotension are usually quickly reversed by fluid infusion and postural management.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
